ARCH Venture Fund IX, L.P. 4
4 · Lyell Immunopharma, Inc. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Lyell (LYEL) ARCH Venture Partners IX Buys 488,090 Shares
What Happened
- ARCH Venture Partners IX, LLC (reported as a 10% owner) purchased 488,090 shares of Lyell Immunopharma (LYEL) in an open market or private purchase on March 6, 2026. The shares were acquired at $25.61 per share for a total reported value of $12,499,985. This is a purchase (often viewed as a bullish signal) by an institutional investor rather than an executive.
Key Details
- Transaction date: 2026-03-06; Price: $25.61 per share; Shares acquired: 488,090; Total value: $12,499,985.
- Filing date: 2026-03-09 — appears timely given the transaction date.
- Shares owned after transaction: Not specified in the provided excerpt.
- Footnotes: The shares are directly held by ARCH Venture Fund IX, L.P. (and related ARCH entities). Several ARCH entities and named managing directors/committee members are listed in the filing and may be deemed to have beneficial interests under SEC rules, but they disclaim beneficial ownership except to the extent of any pecuniary interest. This Form 4 is one of two reports filed jointly by multiple ARCH funds and individuals relating to the same transaction.
Context
- This is an institutional purchase by a venture fund (ARCH), not a company insider like an officer or director. Institutional buys can signal confidence from investors but do not directly indicate management sentiment.
- No options, exercises, gifts, or tax-withholding items are involved in this reported transaction—it's a straight purchase (transaction code P).
Insider Transaction Report
Form 4
ARCH Venture Partners IX, LLC
10% Owner
Transactions
- Purchase
Common Stock
[F1]2026-03-06$25.61/sh+488,090$12,499,985→ 1,426,528 total(indirect: See footnote)
Holdings
- 910,317(indirect: See footnote)
Common Stock
[F2] - 910,317(indirect: See footnote)
Common Stock
[F3]
Footnotes (3)
- [F1]These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
- [F2]These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
- [F3]These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.